A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.
Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 01 Jun 2018
At a glance
- Drugs CV MG01 (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors CuraVac
- 28 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as there were not enough participating centres to complete recruitment in a timely manner
- 19 May 2018 This trial has been Discontinued in Belgium.
- 17 Nov 2017 Planned initiation date changed from 16 Jun 2017 to 1 Jan 2018.